A SYSTEMIC REVIEW AND META ANALYSIS OF PHARMACOLOGICAL TREATMENT OF DEPRESSION IN ADULTS
Main Article Content
Keywords
....
Abstract
Background
Depression, a prevalent mental health disorder affecting millions globally, significantly contributes to worldwide disability. Pharmacological treatment is a common approach for managing moderate to severe depression. Various antidepressant classes are available, including SSRIs, SNRIs, TCAs, and atypical antidepressants. However, patient responses to these medications vary in effectiveness and tolerability. A systematic review and meta-analysis can consolidate evidence from multiple studies to assess the overall efficacy and safety of pharmacological treatments for adult depression.
Methodology
A systematic review and meta-analysis of evaluating pharmacological treatments for adult depression was conducted. Relevant studies were identified through electronic databases such as PubMed, Scopus, and the Cochrane Library using keywords related to depression and antidepressant therapy. Studies including adults aged 18 years and above diagnosed with depression and comparing antidepressants with placebo or other medications were included. Data on treatment outcomes, response rates, remission rates, and adverse effects were extracted.
Findings
The systematic search identified multiple randomized controlled trials evaluating the efficacy of antidepressant medications in adults with depression. After screening and applying inclusion criteria, a number of eligible studies were included in the meta-analysis. The pooled analysis showed that antidepressant medications were significantly more effective than placebo in reducing depressive symptoms and achieving remission. SSRIs such as fluoxetine, sertraline, and citalopram demonstrated consistent effectiveness with relatively fewer adverse effects compared with older antidepressants such as tricyclic antidepressants.
SNRIs, including venlafaxine and duloxetine, also showed strong efficacy, particularly in patients with moderate to severe depression. However, these medications were associated with a slightly higher incidence of side effects such as nausea and increased blood pressure. Tricyclic antidepressants demonstrated comparable effectiveness but were associated with more adverse effects, including anticholinergic symptoms and cardiovascular risks, which may limit their use as first-line therapy. Overall, the meta-analysis indicated that most antidepressants significantly improve depressive symptoms, although differences exist in their tolerability profiles.
Interpretation
The findings of this systematic review and meta-analysis suggest that pharmacological treatments are effective in managing depression in adults. SSRIs and SNRIs appear to offer the best balance between efficacy and tolerability, making them suitable first-line options for most patients.
References
2. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the price. The cost of mental health care in England to 2026. London: King’s Fund; 2021.
3. GreenbergPE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics. 2021; 39(6):653–665.
4. Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2023; 70(9):1219–1229.
5. Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol. 2022; 76(6):909–922.
6. Cuijpers P, van Straten A, van Oppen P, Andersson G. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry. 2021; 69(11):1675–1685. quiz 839-41.
7. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2023; 391(10128):1357–1366.
8. Linde K, Kriston L, Rucker G, et al. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med. 2022; 13(1):69–79.
9. Cuijpers P, Noma H, Karyotaki E, Cipriani A, Furukawa TA. Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: a network meta-analysis. JAMA Psychiatr. 20120; 76(7):700–707.
10. Cuijpers P, Quero S, Noma H, et al. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry. 2021; 20(2):283–293.
11. LindeK,Rucker G, Sigterman K, et al. Comparative effectiveness of psychological treatments for depressive disorders in primary care: network meta-analysis. BMC Fam Pract. 2020; 16:103.
12. Barth J, Munder T, Gerger H, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med. 2022; 10(5):e1001454.
13. Karyotaki E, Efthimiou O and Miguel C, et al. Internet-based cognitive behavioral therapy for depression: a systematic review and individual patient data network meta-analysis. JAMA Psychiatry. 2021;78(4):361–371.
14. Ciharova M, Furukawa TA, Efthimiou O, et al. Cognitive restructuring, behavioral activation and cognitive-behavioral therapy in the treatment of adult depression: a network meta-analysis. J Consult Clin Psychol. 2021;89(6):563–574.
15. Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92–107.
16. Cuijpers P, Oud M, Karyotaki E, et al. Psychological treatment of depression compared with pharmacotherapy and combined treatment in primary care: a network meta-analysis. Ann Fam Med. 2021; 19(3):262–270.
17. Jiang X, Luo Y, Chen Y, et al. Comparative efficacy of multiple therapies for the treatment of patients with sub threshold depression: a systematic review and network meta-analysis. Front Behav Neurosci. 2021; 15:755547.
18. Gartlehner G, Dobrescu A, Chapman A, et al. Nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians. Ann Intern Med. 2023; 176(2):196–211.
19. Noetel M, Sanders T, Gallardo-Gomez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024; 384:e075847.
20. Zimmerman M, Martinez JH, Friedman M, Boerescu DA, Attiullah N, Toba C. How can we use depression severity to guide treatment selection when measures of depression categorize patients differently? J Clin Psychiatry. 2020;73(10):1287–1291.
21. National Institute for Health and Care Excellence. Depression in adults: treatment and management; 2022. Available at: (link unavailable).
22. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2024;162(11):777–784.
23. Carmody TJ, Rush AJ, Bernstein I, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol. 2023;16(8):601–611.
24. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2021;54(5):573–583.
25. Uher R, Farmer A, Maier W, et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med. 2022;38(2):289–300.
26. Wahl I, Lowe B, Bjorner JB, et al. Standardization of depression measurement: a common metric was developed for 11 self-report depression measures. J Clin Epidemiol. 2021;67(1):73–86.
27. Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. CMAJ. 2012;184(3):E191–E196.
28. Lowe B, Spitzer RL, Grafe K, et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. J Affect Disord. 2020;78(2):131–140.
29. Cameron IM, Crawford JR, Lawton K, Reid IC. Psychometric comparison of PHQ-9 and HADS for measuring depression severity in primary care. Br J Gen Pract. 2022;58(546):32–36.
30. Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2020.
31. Spiegelhalter D, Thomas A, Best N, Lunn DJ. WinBUGS user manual: version 1.4. Cambridge: MRC Biostatistics Unit; 2023.
32. LunnD,Jackson C, Best N, Thomas A, Spiegelhalter D. The BUGS book. Boca Raton, FL: CRC Press; 2020.
33. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2020;10:325–337.
34. Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Network meta analysis for decision-making. Hoboken, NJ: Wiley; 2018.
35. Mavridis D, Giannatsi M, Cipriani A, Salanti G. A primer on network meta-analysis with emphasis on mental health. Evid Based Ment Health. 2021;18(2):40–46.
36. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2020;33(5):641–656.
37. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2021;336(7650):924–926.
38. Dias S, Welton NJ, Marinho VCC, Salanti G, Higgins JPT, Ades AE. Estimation and adjustment of bias in randomised evidence by using Mixed Treatment Comparison Meta-analysis. J R Stat Soc Ser A Stat Soc. 2020;173(3):613–629.
39. Moreno SG, Sutton AJ, Turner EH, et al. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ. 2009;339:b2981.
40. Vickery A. ’It’s made me feel less isolated because there are other people who are experiencing the same or very similar to you’: men’s experiences of using mental health support groups. Health Soc Care Community. 2022;30(6):2383–2391.
41. Thimm JC, Antonsen L. Effectiveness of cognitive behavioral group therapy for depression in routine practice. BMC Psychiatry. 2024;14:292.
42. Hieronymus F, Lisinski A, Nilsson S, Eriksson E. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient level post-hoc analysis. Lancet Psychiatry. 2020;6(9):745–752.
43. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2020;303(1):47–53.
44. Riley RD, Dias S, Donegan S, et al. Using individual participant data to improve network meta-analysis projects. BMJ Evid Based Med. 2023;28(3):197–203.
45. Phillippo DM, Dias S, Welton NJ, Caldwell DM, Taske N, Ades AE. Threshold analysis as an alternative to GRADE for assessing confidence in guideline recommendations based on network meta analyses. Ann Intern Med. 2019;170(8):538–546.
46. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e10 03082.
47. Morrison A, Polisena J, Husereau D, et al. The effect of English language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care. 2022;28(2):138–144.
48. Alshehri T, Mook-Kanamori DO, Willems van Dijk K, et al. Metabolomics dissection of depression heterogeneity and related cardiometabolic risk. Psychol Med. 2023;53(1):248–257.
49. NguyenTD,HarderA, XiongY, et al.Geneticheterogeneity and subtypes of major depression. Mol Psychiatry. 2022;27 (3):1667–1675.
50. Buch AM, Liston C. Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics. Neuro psychopharmacology. 2021;46(1):156–175
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Anil Kumar
Associate Professor, Department of Psychiatry, JPMC/JSMU, Karachi
Saba Zehri
Al Tibri Medical College, Karachi
Maham Mehboob
Al Tibri Medical College, Karachi
Usman Ahmed Hashmi
Liaquat National Hospital and Medical College Karachi
Muhammad Hammad Mursaleen
Occupational Therapist, Sindh Institue of Physical Medicine and Rehabilitation
Aaron Anthony John
Occupational Therapist, Dar-Ul-Sukun
Mahjabeen Baloch
SLMO, CIVIL hospital jam Ghulam qadir Hub, Balochistan
Sonia Khan
Associate Professor, Department of Pharmacology, Al Tibri Medical College, Karachi,
